Wakamatsu Akihide, Chinen Madoka, Horio Hiroshi, Chiang Chih-Lin, Tokushige Natsuko, Saga Yosuke
Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan.
Medical Affairs, Janssen Pharmaceutical of Johnson & Johnson, Taipei City, Taiwan.
Neuropsychopharmacol Rep. 2025 Jun;45(2):e70019. doi: 10.1002/npr2.70019.
To examine treatment persistence rates of paliperidone palmitate 3-month (PP3M) for schizophrenia in Japan because evidence in real-world settings is limited.
A retrospective population-based cohort study was conducted using the Japan Medical Data Center claims database. The overall cohort comprised schizophrenia patients aged ≥ 18 years, who received paliperidone palmitate 1-month (PP1M) within 180 days before initiating PP3M. Of patients in the overall cohort, those who received PP1M ≥ 4 times within 180 days at 21-42-day intervals with the same dosage strength as the last two PP1M doses before switching to PP3M initiated PP3M with a dose equivalent to 3.5-fold the last PP1M dose and took no other concomitant antipsychotics within 112 days before initiating PP3M were included in the per protocol cohort (PPC). The Kaplan-Meier method was used to calculate PP3M persistence rates in the overall cohort and PP3M monotherapy persistence rates in the PPC.
In the overall cohort and PPC, 121 patients and 87 patients, with a mean age of 41.5 years and 48%-53% being employed, were followed up for ≤ 27 months. At 365 days and 730 days, the PP3M persistence rate was 76.9% and 71.7% in the overall cohort, and that for PP3M monotherapy was 73.1% and 64.6% in the PPC.
Treatment persistence rates for PP3M in Japan were relatively high among schizophrenia patients transitioned from PP1M. High persistence rates can be achieved with PP3M monotherapy in patients who have been sufficiently stabilized with PP1M monotherapy prior to initiating PP3M.
鉴于现实环境中的证据有限，本研究旨在调查日本使用棕榈酸帕利哌酮3个月剂型（PP3M）治疗精神分裂症的治疗持续率。
利用日本医疗数据中心的索赔数据库进行了一项基于人群的回顾性队列研究。整个队列包括年龄≥18岁的精神分裂症患者，他们在开始使用PP3M前180天内接受过棕榈酸帕利哌酮1个月剂型（PP1M）治疗。在整个队列的患者中，那些在180天内以21 - 42天的间隔接受PP1M≥4次，且剂量强度与转换为PP3M前最后两次PP1M剂量相同的患者，开始使用剂量相当于最后一次PP1M剂量3.5倍的PP3M治疗，并且在开始使用PP3M前112天内未服用其他任何抗精神病药物的患者被纳入符合方案队列（PPC）。采用Kaplan - Meier方法计算整个队列中的PP3M持续率以及PPC中的PP3M单药治疗持续率。
在整个队列和PPC中，分别对121例患者和87例患者进行了随访，平均年龄分别为41.5岁，就业比例分别为48% - 53%，随访时间≤27个月。在365天和730天时，整个队列中的PP3M持续率分别为76.9%和71.7%，PPC中PP3M单药治疗的持续率分别为73.1%和64.6%。
在从PP1M转换而来的精神分裂症患者中，日本PP3M的治疗持续率相对较高。对于在开始使用PP3M之前已通过PP
